drugset / Trial / NCT02186600

Heartland Osteoporosis Prevention Study

NCT02186600 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take calcium and vitamin D only; 2) who take calcium and vitamin D plus the medication "risedronate"; or 3) who take calcium and vitamin D plus participate in bone-loading exercises. Our central hypothesis is that improvements in bone health will be greater in women randomized to bone-loading exercises with calcium and vitamin D compared to women who take calcium and vitamin D only or women who take calcium and vitamin D plus risedronate.

Timeline

Start
2015-02-01
Primary completion
2019-06-01
Completion
2019-06-01

Outcome

Missed primary endpoint

registry analysis (other test); Control vs Risedronate vs Exercise; p = 0.7; hierarchical linear modeling NCT02186600 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Risedronate Small molecule 35 mg Oral
Background Calcium carbonate Other / unclassified 1200 mg —
Background Cholecalciferol Other / unclassified 1000 iu —
Background Cholecalciferol Other / unclassified 2000 iu —
Background Cholecalciferol Other / unclassified 3000 iu —

Indications

No indication recorded.